Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm

This article was originally published in PharmAsia News

Executive Summary

Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region

You may also be interested in...



Jordan’s Hikma Sails On Strong Winds From Injectables, But Generics Lag

A slower than expected remediation process with U.S. FDA for its Eatontown, New Jersey, plant has cast a shadow on Hikma’s generics business and may lead to a restructuring or even sale of the unit.

Jordan’s Hikma Continues Buying Spree In MENA With Egypt Acquisition

Hikma will acquire Egypt’s EPCI as part of its strategy to grow in the Middle East and North Africa region. It has its sites on Turkey, but says acquisition targets are too pricey for now.

Quintiles Continues Eastward Push, Looks To Russia And Middle East For Growth

The U.S. CRO sees opportunities to align with young, domestic biopharma companies in emerging markets.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel